

ASX Announcement**Imugene attaches an Appendix 3Y – Change of Director’s Interest Notice for Executive Chairman, Mr Paul Hopper**

Sydney, Australia, 13 December 2021: Imugene Limited (ASX:IMU) a clinical stage immuno-oncology company today announced that Executive Chairman, Mr Paul Hopper, through associated family entities, has sold 75 million shares in an off-market block trade, to an institutional investor. Other details include:

- The ordinary shares sold represent 1.3% of Imugene’s fully paid ordinary shares on issue and approximately 19% of Mr Hopper’s.
- This is the first significant sale made by Mr Hopper since founding the company 8 years ago
- Mr Hopper obtained the necessary approvals pursuant to the company’s ‘Policy for Trading in Company Securities’ prior to entering into the sale.

Mr Hopper said “As the Founder, Executive Chairman and largest shareholder of the Company, I remain committed to Imugene and I am very excited about its prospects. The sale relates to a portion of my exposure to Imugene, which remains substantial, and has become necessary due to my personal circumstances including portfolio balancing, estate planning for my family and taxation obligations. I look forward to continuing to drive success for the company and its shareholders.”

For more information please contact:

Phillip Hains
Company Secretary
T: +61 3 98644839
E: phillip@thecfo.com.au

Follow us on Twitter @TeamImugene
Like us on Facebook @Imugene
Connect with us on LinkedIn @Imugene Limited

About Imugene (ASX:IMU)

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Our unique platform technologies seek to harness the body’s immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and

other immunotherapies. Our product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T's for solid tumours. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugene's immunoncology therapies will become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.

Release authorised by the Managing Director and Chief Executive Officer

Imugene Limited, Level 3, 62 Lygon Street, Carlton, VIC, 3053, Australia

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001. Amended 01/01/11

Name of Entity:	Imugene Limited (ASX: IMU)
ACN:	009 179 551

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Paul Hopper
Date of Last Notice:	22 October 2021

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or Indirect Interest	Direct and Indirect		
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Director related entity		
Date of change	13 December 2021		
No. of securities held prior to change		Shares	Options
	Direct	3,607,500	-
	Indirect	388,524,148	-
	Total	392,131,648	-
Class	Fully paid ordinary shares		
Number acquired		Shares	Options
	Direct	-	-
	Indirect	-	-
	Total	-	-
Number disposed		Shares	Options
	Direct	1,248,900	-
	Indirect	73,751,100	-
	Total	75,000,000	-

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$0.49 per share		
No. of securities held after change		Shares	Options
	Direct	2,358,600	-
	Indirect	314,773,048	-
	Total	317,131,648	-
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	On-Market.		

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

+ See chapter 19 for defined terms.

For personal use only

Part 3 – Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A



13 December 2021

+ See chapter 19 for defined terms.

For personal use only